Recently, Ningbo Kunpeng Biotechnology Co., Ltd., which is undertaken by Guoruitai Company of National Pharmaceutical Engineering, has an annual output3000 ten thousand insulin injection project officially entered the full acceptance stage. At present, the module manufacturing, field installation, operation and commissioning, verification and execution of the fluid system of the workshop process tube and tank have been completed.

Ningbo Kunpeng Biological Co., Ltd. since its inception, has always been committed to insulin, GLP-1 focusing on the three core technologies of "non-natural amino acid protein synthesis", "protein fixed-point modification" and "nano-drug loading", the traditional insulin production process has been overturned. At the same time, relying on the core technology, an efficient long-acting protein drug research and development platform has been established. Now, the pipeline has been expanded to more than ten dosage forms in two categories, including the fourth generation of ultra-long-acting insulin and the new type of selaglutide, has applied for more than 100 patents of independent intellectual property rights at home and abroad, and obtained authorization.21 item. 

The process tube fluid system undertaken by Guoritai Company of National Pharmaceutical Engineering is the core system of the whole production line, which will help Kunpeng Bio to continue to innovate and forge ahead in the future, bring new growth force to its local pharmaceutical industry, and promote the high-quality innovation and development of regional economy.